Connect with us

Health

Prostate cancer drug now available to more patients with aggressive form of disease

Published

on

Prostate cancer drug now available to more patients with aggressive form of disease

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease.

Novartis, a Switzerland-based pharmaceutical company, announced on March 28 that the U.S. Food and Drug Administration (FDA) has expanded approval for Pluvicto (lutetium Lu 177 vipivotide tetraxetan), a targeted radioligand therapy (RLT) that is given before chemotherapy.

(RLTs are a form of targeted nuclear medicine that doctors use to treat multiple types of cancer, according to Novartis.)

PROSTATE CANCER RISK INCREASES BY 45% AMONG MEN WHO SHARE ONE TROUBLING BEHAVIOR

The drug is intended for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) who have received one round of androgen receptor pathway inhibitors (ARPIs), a class of drugs used in the treatment of metastatic prostate cancer.

Advertisement

A newly expanded prostate cancer drug could bring new hope to patients with a common form of the disease. (iStock)

Pluvicto first got FDA approval on March 23, 2022, but this new expanded approval triples the number of patients eligible to receive the drug, according to a Novartis press release.

The drug is administered through an IV into the bloodstream, where it attaches to prostate cancer cells and either keeps them from replicating or kills them.

PROSTATE CANCER CASES SPIKE IN THIS US STATE AS DOCTORS SHARE LIKELY REASON

“The earlier indication for Pluvicto could really change our treatment paradigms for patients with mCRPC,” said lead study author Michael Morris, MD, prostate cancer section head at Memorial Sloan Kettering Cancer Center in New York. 

Advertisement

“It offers a targeted therapy that better delays disease progression compared to a second ARPI. This approval is a significant step forward and should open the doorway to a therapy that has clear clinical advantages for the patient with mCRPC who has progressed on one ARPI and has not received chemotherapy.”

In clinical trials, Pluvicto “significantly reduced the risk of progression or death” by 59%.

This is a form of prostate cancer that has spread to other parts of the body and does not respond to standard hormone therapy, according to WebMD. 

It also has high levels of prostate-specific membrane antigen (PSMA), a protein produced by prostate cancer cells. 

In clinical trials, Pluvicto “significantly reduced the risk of progression or death” by 59% in mCRPC patients, Novartis reported.

Advertisement

IMAGE

“The FDA’s expanded approval of [lutetium Lu 177 vipivotide tetraxetan] marks a transformative step forward in the treatment of mCRPC, underscoring the growing impact of precision oncology,” Jorge A. Garcia, MD, a genitourinary medical oncologist and chair of the Solid Tumor Oncology Division at University Hospitals Seidman Cancer Center/Case Western Reserve University in Cleveland, Ohio, told OncLive. 

      

“By enabling access to this targeted radioligand therapy prior to chemotherapy, we are not only broadening treatment options, but also redefining the standard of care for PSMA-positive disease.”

“By enabling access to this targeted radioligand therapy prior to chemotherapy, we are not only broadening treatment options, but also redefining the standard of care for PSMA-positive disease,” a researcher said. (iStock)

Advertisement

Prostate cancer is the second leading cause of death among men; mCRPC makes up a majority of the deaths and 20% of all metastatic prostate cancer cases.

Studies have shown that approximately 10% to 20% of patients with prostate cancer develop mCRPC within five years of follow-up after initial therapy, and cases of metastatic patients have risen 4% to 5% each year since 2011.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

Sixty percent of prostate cancers are diagnosed in men who are 65 or older, according to the American Cancer Society. The risk of being diagnosed with metastatic prostate cancer typically occurs between 65 and 74.

Adverse effects of Pluvicto included dry mouth (61%), fatigue (53%), nausea (32%) and constipation (22%), the release stated. 

Advertisement

Prostate cancer is the second leading cause of death among men; mCRPC makes up a majority of the deaths and 20% of all metastatic prostate cancer cases. (iStock)

The patients receiving the drug were able to proceed with chemotherapy after taking it.

Novartis is committed to delivering Pluvicto to the nearly 600 RLT treatment sites in the U.S., the company stated.

For more Health articles, visit www.foxnews.com/health

Looking ahead, Novartis said it plans to investigate the use of RLTs for other types of advanced cancers, including breast, colon, neuroendocrine, lung and pancreatic cancers.

Advertisement

Health

Origin of deadly cancer affecting young adults revealed in alarming report

Published

on

Origin of deadly cancer affecting young adults revealed in alarming report

NEWYou can now listen to Fox News articles!

As colorectal cancer (CRC) is now the leading cause of cancer death in adults under 50, a new report reveals some surprising shifts in the incidence of the disease.

Although rates of CRC have been declining among seniors, those 65 and under are facing a rise in diagnoses, according to a report titled Colorectal Cancer Statistics, 2026, from the American Cancer Society.

Adults 65 and younger comprise nearly half (45%) of all new colorectal cancer cases — a significant increase from 27% in 1995, states the report, which was published in CA: A Cancer Journal for Clinicians.

The disease is rising fastest among adults 20 to 49 years old, at a rate of 3% per year.

Advertisement

Colorectal cancer is now the leading cause of cancer death in adults under 50. (iStock)

Among adults 50 and under, 75% of colorectal cancers are diagnosed at an advanced stage. Half of the diagnoses in that age range are made between the ages of 45 and 49. Although that age group is eligible to receive routine screenings, just 37% do so.

CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER

The report also revealed that rectal cancer is on the rise, now accounting for about one-third (32%) of all CRC cases — an increase from 27% in the mid-2000s.

CLICK HERE FOR MORE HEALTH STORIES

Advertisement

“After decades of progress, the risk of dying from colorectal cancer is climbing in younger generations of men and women, confirming a real uptick in disease because of something we’re doing or some other exposure,” said Rebecca Siegel, senior scientific director, surveillance research at the American Cancer Society and lead author of the report, in a press release.

Among adults 50 and under, 75% of colorectal cancers are diagnosed at an advanced stage. Half of the diagnoses in that age range are made between the ages of 45 and 49.  (iStock)

“We need to redouble research efforts to understand the cause, but also circumvent deaths through earlier detection by educating clinicians and the general public about symptoms and increasing screening in people 45-54 years.”

It is projected that 158,850 new cases of colorectal cancer will be diagnosed this year, and that the disease will cause 55,230 deaths, per the report.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Advertisement

More than half of CRC cases can be linked to high-risk behaviors, the researchers said. Those include lack of nutrition, high alcohol consumption, smoking, lack of exercise and obesity.

“These findings further underscore that colorectal cancer is worsening among younger generations and highlight the immediate need for eligible adults to begin screening at the recommended age of 45,” said Dr. William Dahut, chief scientific officer at the American Cancer Society.

When the disease is caught at a local (early) stage, the five-year survival rate is 95%. (iStock)

“The report also shines a light on the crucial importance of continued funding for research to help discover new therapies to treat the disease and advance patient care.”

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Advertisement

When the disease is caught at a local (early) stage, the five-year survival rate is 95%, the report stated.

Related Article

Hidden virus inside gut bacteria linked to doubled colorectal cancer risk, study finds
Continue Reading

Health

Aging process could accelerate due to ‘forever chemicals’ exposure, study finds

Published

on

Aging process could accelerate due to ‘forever chemicals’ exposure, study finds

NEWYou can now listen to Fox News articles!

A new study suggests that middle-aged men may be more vulnerable to faster biological aging, potentially linked to exposure to “forever chemicals.”

The research, published in the journal Frontiers in Aging, examined how perfluoroalkyl and polyfluoroalkyl substances, more commonly known as PFAS, could impact aging at the cellular level.

PFAS are synthetic chemicals commonly used in nonstick cookware, food packaging, water-resistant fabrics and other consumer products, the study noted. 

Their chemical structure makes them highly resistant to breaking down, allowing them to accumulate in water, soil and the human body.

Advertisement

Chinese researchers analyzed blood samples from 326 adults enrolled in the U.S. National Health and Nutrition Examination Survey between 1999 and 2000.

A new study suggests that middle-aged men could face accelerated biological aging at the cellular level due to exposure to PFAS. (iStock)

The researchers measured levels of 11 PFAS compounds in participants’ blood and used DNA-based “epigenetic clocks” — tools that analyze chemical changes to DNA to estimate biological age — to determine how quickly their bodies were aging at the cellular level, the study stated.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

Two compounds, perfluorononanoic acid (PFNA) and perfluorooctanesulfonamide (PFOSA), were detected in 95% of participants.

Advertisement

Higher concentrations of those chemicals were associated with faster biological aging in men of certain age groups, but not in women.

“People should not panic.”

The compounds most strongly linked to accelerated aging were not the PFAS chemicals that typically receive the most public attention, the researchers noted.

CLICK HERE TO DOWNLOAD THE FOX NEWS APP

“The associations were strongest in adults aged 50 to 64, particularly in men,” Dr. Xiangwei Li, professor at Shanghai Jiao Tong University School of Medicine and the study’s corresponding author, told Fox News Digital. 

Advertisement

“While this does not establish that PFAS cause aging, it suggests that these widely present ‘forever chemicals’ may be linked to molecular changes related to long-term health and aging.”

The study found that two of the compounds were detected in 95% of participants, and higher levels were linked to faster biological aging in men ages 50–64. (iStock)

Midlife may represent a more sensitive biological period, when the body becomes more vulnerable to age-related stressors, according to the researchers.

Lifestyle factors, such as smoking, may influence biological aging markers, potentially increasing vulnerability to environmental pollutants.

Advertisement

While Li said “people should not panic,” she does recommend looking for reasonable ways to reduce exposure. 

That might mean checking local drinking water reports, using certified water filters designed to reduce PFAS, and limiting the use of stain- or grease-resistant products when alternatives are available.

CLICK HERE FOR MORE LIFESTYLE STORIES

Meaningful reductions in PFAS exposure will likely depend on broader regulatory action and environmental cleanup efforts, Li added.

The researchers noted that midlife could be a particularly sensitive stage, when the body is more susceptible to stressors associated with aging. (iStock)

Advertisement

Study limitations

The researchers outlined several important limitations of the research, including that the findings show an association, but do not prove that PFAS directly causes accelerated aging.

“The study is cross-sectional, meaning exposure and aging markers were measured at the same time, so we cannot determine causality,” Li told Fox News Digital.

The study was also relatively small, limited to 326 adults age 50 or older, which means the findings may not apply to younger people or broader populations.

TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ

Researchers measured PFAS levels using data collected between 1999 and 2000, and today’s exposure patterns may differ.

Advertisement

Li added that while PFAS is known to persist in the environment and the body, these results should be validated through larger, more recent studies that follow participants over time.

Related Article

Nightly bathroom habit was missed sign of common men's cancer: 'I didn't know'
Continue Reading

Health

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause

Published

on

Melissa Joan Hart, 49, Opens up About Weight Loss in Perimenopause


Advertisement




Melissa Joan Hart Opens up About Weight Loss in Perimenopause | Woman’s World




















Advertisement





Advertisement


Use left and right arrow keys to navigate between menu items.


Use escape to exit the menu.

Advertisement

Continue Reading

Trending